Page last updated: 2024-10-17
fosmidomycin and Pyrexia
fosmidomycin has been researched along with Pyrexia in 1 studies
fosmidomycin: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source
fosmidomycin : Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Fosmidomycin-clindamycin is a promising novel treatment option for malaria." | 6.71 | Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. ( Adegnika, AA; Borrmann, S; Esser, G; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Matsiegui, PB; Mawili-Mboumba, DP; Missinou, MA; Oyakhirome, S; Ramharter, M, 2004) |
| "Fosmidomycin-clindamycin is a promising novel treatment option for malaria." | 2.71 | Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. ( Adegnika, AA; Borrmann, S; Esser, G; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Matsiegui, PB; Mawili-Mboumba, DP; Missinou, MA; Oyakhirome, S; Ramharter, M, 2004) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Borrmann, S | 1 |
| Issifou, S | 1 |
| Esser, G | 1 |
| Adegnika, AA | 1 |
| Ramharter, M | 1 |
| Matsiegui, PB | 1 |
| Oyakhirome, S | 1 |
| Mawili-Mboumba, DP | 1 |
| Missinou, MA | 1 |
| Kun, JF | 1 |
| Jomaa, H | 1 |
| Kremsner, PG | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria[NCT00214643] | Phase 3 | 160 participants | Interventional | 2005-06-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for fosmidomycin and Pyrexia